Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,793,178
  • Shares Outstanding, K 657,644
  • Annual Sales, $ 1,349 M
  • Annual Income, $ 478,570 K
  • 60-Month Beta 0.86
  • Price/Sales 17.40
  • Price/Cash Flow 45.28
  • Price/Book 6.85
Trade GMAB with:

Options Overview Details

View History
  • Implied Volatility 53.08% ( -0.32%)
  • Historical Volatility 30.29%
  • IV Percentile 55%
  • IV Rank 39.02%
  • IV High 82.78% on 06/14/22
  • IV Low 34.08% on 01/20/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 26
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 2,257
  • Open Int (30-Day) 2,215

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 0.23
  • Number of Estimates 5
  • High Estimate 0.25
  • Low Estimate 0.21
  • Prior Year 0.21
  • Growth Rate Est. (year over year) +9.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.80 +12.55%
on 07/13/22
38.17 -3.29%
on 08/11/22
+3.58 (+10.76%)
since 07/12/22
3-Month
26.19 +40.95%
on 06/16/22
38.17 -3.29%
on 08/11/22
+8.60 (+30.35%)
since 05/12/22
52-Week
26.19 +40.95%
on 06/16/22
49.07 -24.77%
on 09/02/21
-9.65 (-20.72%)
since 08/12/21

Most Recent Stories

More News
Genmab A/S (GMAB) Q2 2022 Earnings Call Transcript

GMAB earnings call for the period ending June 30, 2022.

GMAB : 36.94 (-2.02%)
Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; August 8, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back...

0MGB.LN : 2,636.000 (-3.18%)
GMAB : 36.94 (-2.02%)
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

COPENHAGEN, Denmark; August 5, 2022  Collaboration expands to include development of monospecific antibody candidates to address malignant solid...

0MGB.LN : 2,636.000 (-3.18%)
GMAB : 36.94 (-2.02%)
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates

Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the...

GMAB : 36.94 (-2.02%)
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab A/S (Nasdaq: GMAB) today announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) with the European Medicines Agency (EMA) for subcutaneous epcoritamab...

GMAB : 36.94 (-2.02%)
ABBV : 142.34 (+0.18%)
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Company Announcement COPENHAGEN, Denmark; July 18, 2022 – Genmab A/S (Nasdaq: GMAB) today announced that AbbVie (NYSE: ABBV) will submit a conditional...

0MGB.LN : 2,636.000 (-3.18%)
GMAB : 36.94 (-2.02%)
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Company Announcement COPENHAGEN, Denmark; June 30, 2022 – Genmab A/S (Nasdaq: GMAB) today announced its intent to submit a biologics license application...

0MGB.LN : 2,636.000 (-3.18%)
GMAB : 36.94 (-2.02%)
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; June 23, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market...

0MGB.LN : 2,636.000 (-3.18%)
GMAB : 36.94 (-2.02%)
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Media Release COPENHAGEN, Denmark; June 11, 2022  Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory...

0MGB.LN : 2,636.000 (-3.18%)
GMAB : 36.94 (-2.02%)
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S (Nasdaq: GMAB) announced today primary results from the large B-cell lymphoma (LBCL) expansion cohort in the EPCORE™ NHL-1 phase 2 clinical trial evaluating subcutaneous epcoritamab (DuoBody...

GMAB : 36.94 (-2.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 39.08
2nd Resistance Point 38.63
1st Resistance Point 38.16
Last Price 36.94
1st Support Level 37.24
2nd Support Level 36.79
3rd Support Level 36.32

See More

52-Week High 49.07
Fibonacci 61.8% 40.33
Fibonacci 50% 37.63
Last Price 36.94
Fibonacci 38.2% 34.93
52-Week Low 26.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar